Bone health, joint preservation and cartilage repair

October 6 sponsor announcement. Smith+Nephew reports commercial availability of the CARTIHEAL AGILI-C cartilage-repair implant in twelve European markets. This is an access update, not a new October clinical readout.

U.S.: The FDA originally approved AGILI-C on March 29, 2022 for specified grade III-or-higher knee-joint surface lesions totaling 1–7 cm², without severe osteoarthritis (Kellgren–Lawrence 0–3). It is a surgical scaffold for selected defects, not a general cure for advanced knee arthritis.

The cited five-year randomized trial was published online April 16, 2026. Its abstract supports better symptom/function scores versus microfracture or debridement, but full harms and reoperation tables remain an appraisal gap here. Do not interpret cartilage repair as proven avoidance of joint replacement in all patients.

Sources: smith-nephew.com · news release; FDA · device approval record; PubMed · PMID 41992573.

Remaining gaps: All saved named registry records and every page of bounded September 5–October 16 CT.gov discovery were retrieved; 112 discovery records were screened selectively. Retrieval is not full appraisal. Worldwide registries, all publications/regulatory files, complete harms and original audio/transcripts remain incomplete. Prior full successful-check dates are preserved. AGILI-C full five-year harms/reoperation tables and TG-C ACTiVION-I October disclosure remain unresolved; no outcome inferred from elapsed forecasts.

Informal-source coverage: Targeted Reddit, interview, podcast and saved unresolved-claim searches were appraised selectively; original recordings and worldwide informal coverage remain incomplete. Routine anecdotes and reposts were not treated as new trial evidence.

Full coverage record.

Registry updated October 13, 2026; primary-completion event September 18. NCT04467983 compares adding daily abaloparatide 80 micrograms to continued denosumab with denosumab alone in postmenopausal women with osteoporosis who have received at least four denosumab treatments. The randomized open-label phase 4 trial lists 70 estimated participants, not an actual analyzed denominator. Its primary endpoint is 18-month hip/spine bone-mineral-density change.

Status/limits/safety: Active, not recruiting; no results are posted. Actual primary completion does not imply a positive result, final study completion or a publication date. Density is a surrogate; this trial does not establish fewer fractures or better fracture healing. No new safety rates. Existing approvals for the individual drugs do not establish approval or superiority for this combination strategy.

Next: Final completion remains December 31, 2026 estimated; public release date unknown.

Sources: ClinicalTrials.gov · NCT04467983.

Remaining gaps: All saved named registry records retrieved and all pages of bounded September5/6–October13 CT.gov discovery downloaded; 99 records screened selectively. Retrieval is not full appraisal. Worldwide registries, all publications/regulatory files, comprehensive harms and full audio/transcripts remain incomplete; prior full successful-check dates preserved.

Informal-source coverage: Targeted original Reddit/new cartilage and osteoporosis program searches yielded no distinctive attributable development claim selected; full conference/podcast recordings remain unreviewed. This limited search is not absence of rumors.

Full coverage record.

Source date: October 2, 2026; newly appraised October 9. LoRD-KNeA (NCT05562271) randomized 114 adults aged at least 50 with walking pain 50–90/100 to sham, 0.3 Gy or 3 Gy, each radiation regimen in six fractions. In the modified intention-to-treat analysis, four-month OMERACT–OARSI response was 70.3% with 3 Gy versus 41.7% with sham (p=.021); 0.3 Gy yielded 58.3% (p=.168 versus sham). The higher-dose response advantage persisted at eight months but was not statistically significant at twelve months.

Limits/safety: Continuous WOMAC, pain, global-assessment, inflammatory and MRI endpoints did not differ significantly. No treatment-related toxicities were reported in the abstract; this small, short study cannot resolve rare or delayed radiation harms. No proven cartilage regeneration, fracture benefit or avoided joint replacement. The registry masks participants; full PDF and supplemental safety tables were not appraised. Early accepted article may receive editorial changes.

U.S./next: This is research on a procedure, not a U.S. approval or general recommendation. Independent replication and durable clinical/late-safety assessment have no announced dates.

Published abstract; primary registry.

Remaining gaps: All saved named NCT records refreshed and all pages of official overlap discovery screened (96 returned records). Search starts September 5/6 from the last full successful check, not October 6 alone. Incidental matches excluded; literature, international registries, all regulatory files and complete podcast/audio appraisal remain incomplete.; No new ACTiVION-I October topline or lorecivivint regulatory decision verified. Cartilage-cell and osteoporosis programs refreshed in registries; complete fracture/sequencing literature remains incomplete. EB613 October 9/11 ASBMR slots were recovered from an August announcement; no new efficacy inferred before presentation.

Informal-source coverage: Original Osteoarthritis Reddit discovery returned recycled lorecivivint/sprifermin forecasts and injection anecdotes rather than a dated new formal-development claim. Broad original podcast review remains a gap.

Full coverage record.

Source date: October 2, 2026; event: EMA validation September 30. Evidence: Biosplice’s original GlobeNewswire release, retrieved through its syndication.

The sponsor reports that EMA validated the lorecivivint marketing application for knee osteoarthritis, beginning centralized review. UK validation was August 28 and announced September 8. The previously elapsed September filing window can now be resolved as a sponsor-reported regulatory milestone.

Limits/safety: Validation establishes dossier completeness, not a favorable benefit-risk decision. Promotional claims about OA-07 joint-space width and pain do not constitute a newly appraised controlled dataset; preserve earlier mixed trial findings and extension limitations. This release adds no independently appraised safety table.

U.S./next milestone: The sponsor explicitly says lorecivivint is not approved by EMA, MHRA, FDA or another regulator. No reliable decision date was disclosed; follow review outcomes separately.

Syndicated original sponsor release; sponsor news index.

Baseline, not new October efficacy: NCT07339111 was first posted January 14, 2026. The October 6 registry lists recruiting, with actual start March 11, 2026.

This masked randomized phase 3 study plans 300 adults aged 18–75 with knee cartilage lesions/osteoarthritis. CARTISTEM (umbilical-cord-blood-derived stromal cells with hyaluronate) plus debridement is compared with debridement alone. Co-primary outcomes are 24-month VAS pain and WOMAC function; MRI cartilage scores are secondary.

Limits/safety/U.S.: No efficacy or safety results are posted; a cell implant’s presence or an imaging gain would not prove avoided knee replacement. U.S. trial participation is distinct from marketing approval.

Next: June 30, 2029 primary/final completion is estimated, not a publication promise.

Primary registry.

Source date: 2026-09-25. Evidence: Peer-reviewed extension of open-label randomized trial; abstract reviewed.

A one-year extension examines denosumab after differing prior denosumab/zoledronate sequences. At 36 months the abstract reports no significant between-group difference in BMD change during extension or fractures; bone-turnover markers were lower after prior zoledronate. Both groups received denosumab in year three. Parent registry NCT03868033 enrolled 101, but extension denominators are not supplied in the abstract.

Limitations: No numerical BMD estimates, confidence intervals or fracture counts recovered. Nonsignificance does not establish equivalence; parent-trial enrollment must not substitute for extension sample size.

Safety: Detailed adverse-event and rebound-fracture tables require full-paper appraisal.

U.S. status: Existing drugs; no new U.S. indication or universal switching recommendation.

Next milestone: Full paper and long-term fracture/safety replication; no announced date.

Original September 25 publication; Denosumab sequential parent registry.

Source date: 2026-09-22. Event date: 2026-09-22. Evidence: Peer-reviewed Phase 1 abstract and trial registry.

The sclerostin antibody has a small first-human report and a newly registered comparative Phase 2 trial. NCT05391776: 32 Chinese adults with low BMD, single IV dose/placebo, 85-day follow-up; 24 received TST002. Abstract reports lumbar-spine BMD/biomarker changes without precise effect estimates. NCT07806331 plans 110 women across three TST002 regimens, placebo and open-label denosumab; 24-week lumbar BMD primary endpoint.

Limitations: No demonstrated fracture reduction. Phase 1 is small/single-dose; formation markers unavailable. Phase 2 registry labels intervention model SINGLE_GROUP despite describing randomized multiple arms: unresolved coding inconsistency.

Safety: Most Phase 1 treatment-related AEs were grade 1; full event tables not appraised. Long-term and cardiovascular safety unestablished.

U.S. status: Investigational.

Next milestone: Phase 2 not yet recruiting; estimated start October 31, 2026, primary completion April 30, 2027, final October 31, 2028.

Primary TST002 abstract; Original article; TST002 Phase 2 registry.

Related findings:

• SOLARIO supports shorter systemic antibiotics when surgery includes local antibiotic implants.

Source date: 2026-04-01. Event date: 2026-04-01. Evidence: Older trial-registry record rechecked; not new trial initiation.

NCT07112443 is a registered phase 3 randomized study of NVD003 versus iliac-crest bone graft for congenital pseudarthrosis of the tibia. Target enrollment 12 children; actual start September 2, 2025. Overall healing requires radiographic union, pain-free weight-bearing and no secondary healing intervention at 12 months.

Limitations: A rare pediatric nonunion indication, not generalized osteoporosis or ordinary fracture repair. The registry was last updated April 1, 2026; current operational progress and results remain unverified.

Safety: No results posted.

U.S. status: Investigational.

Next milestone: Primary completion estimated October 2026; final completion July 2027. These stale estimates are not publication dates.

Original registry.

Source date: 2026-09-07. Evidence: Peer-reviewed randomized trial; primary abstract reviewed.

The Finnish FIND trial found no fracture reduction from 1,600 or 3,200 IU/day in older adults who were largely vitamin-D sufficient. NCT01463813 randomized 2,495 adults to the two doses or placebo. Over mean 4.1 years of supplementation, fractures numbered 73, 52 and 49 respectively: HR 1.52 (95% CI 1.06–2.18) for 1,600 IU and 1.07 (0.72–1.58) for 3,200 IU versus placebo. Extended follow-up also showed no benefit.

Limitations: Baseline vitamin D was measured in a 550-person subcohort (mean 74.8 nmol/L). This does not answer treatment of established deficiency or all high-risk osteoporosis populations. No simple dose-response explanation is established by the lower-dose imbalance.

Safety: The increased fracture rate in the 1,600-IU group is retained as a safety-relevant finding; fracture subtypes did not differ significantly. Detailed non-fracture adverse events were not available in the abstract.

U.S. status: A research result, not a new drug approval or individualized supplementation instruction.

Next milestone: Full-paper appraisal and replication; no dated next milestone.

Original abstract, September 7; Article.

Related findings:

• An antimicrobial peptide is being tested against prosthetic-joint infection: WVU reported its first participant in RETAIN, a controlled trial of PLG0206 irrigation alongside surgery and antibiotics for infected knee replacements.

Lorecivivint / LOR / SM04690 is an intra-articular small molecule targeting CLK/DYRK kinases and modulating Wnt signaling. Biosplice announced on January 6, 2026 that it had submitted a U.S. NDA in late 2025. Its current program page describes favorable pain, function, and radiographic joint-space findings, particularly from the OA-07 extension, but explicitly says the drug is not FDA approved. These are sponsor interpretations of the submission, not an FDA determination that joint regeneration or disease modification has been established. NDA announcement; current sponsor program.

The peer-reviewed OA-10 phase 3 trial, NCT04385303, failed its primary pain endpoint at week 12 in the full analysis population. Other efficacy endpoints were also not significantly different; adverse-event patterns were similar between groups. A favorable post-hoc finding in less structurally severe disease does not reverse the overall result. OA-07, NCT04520607, is an extension study: the analysis population, repeat dosing, missing data, and available controlled comparisons matter when interpreting long-term joint-space changes. OA-10 publication; OA-07 registry.

On September 8, 2026, Biosplice reported that the UK MHRA accepted its application for assessment and that an EMA submission was planned later that month. Acceptance begins review; it is not authorization. No reliable U.S. FDA decision date was verified for this baseline. September company announcement.

TissueGene-C / TG-C, Kolon TissueGene's injected allogeneic cell/gene therapy, remains investigational in the U.S. On July 20, 2026, the sponsor reported that ACTiVION-II, NCT03291470, randomized 531 people with knee OA but missed both co-primary endpoints: pain and total WOMAC score at 12 months. It also missed every key secondary endpoint. The company reported comparable adverse-event patterns and no new safety signal, but detailed independent review of the full dataset is still needed.

The second U.S. phase 3 trial, ACTiVION-I, NCT03203330, is expected to report in October 2026, after which the company plans to determine next steps. This is a high-priority update: assess replication, effect sizes and confidence intervals, and any explanation offered for discordant results. The earlier positive phase 2 narrative cannot substitute for the failed phase 3 evidence. Sponsor's phase 3 topline report and October timeline.

Sprifermin, recombinant human FGF18, remains a phase 2 knee OA program on Formation Bio's current pipeline; no U.S. approval or firm next pivotal readout date was verified. In FORWARD, NCT01919164, the 549-participant randomized trial found increased MRI-measured cartilage thickness with higher doses, but not a significant overall symptomatic benefit at two years. Current pipeline; primary randomized trial.

At five years, 378 participants remained; the highest-dose schedule retained a roughly 0.05 mm cartilage-thickness difference versus placebo. Pain improved substantially in all groups. An exploratory higher-risk subgroup does not establish broad pain relief or avoidance of surgery, and attrition limits the long-term comparison. Future trials need prespecified clinical outcomes alongside structural measurements. Peer-reviewed five-year follow-up.